2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4681 Treatment exposure and acute-care utilisation in adults with HbSS or HbSβ⁰thalassaemia: A harmonised analysis of the UK SCD natural history study and US SCD grndad registry

Alvin M Katumba, MBBS MRCP MRes, Vinal Menon2, Claudine R Sun3, Sara Stuart-Smith4, Jane A Little, MD5, Sophie Lanzkron, MD, MHS6, Kate Gardner7
1 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
2 Johns Hopkins University, Baltimore, Maryland, United States
3 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
4 King's College Hospital NHS Foundation Trust, London, United Kingdom
5 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
6 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
7 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Background: Adults with sickle cell disease (SCD) experience significant acute morbidity despite increasing availability of disease-modifying therapies (DMTs). International comparisons can identify variation in treatment patterns and healthcare use, but are complicated by differences in genotype distribution, variable definitions and healthcare delivery. We harmonised two contemporary UK and US cohorts to describe differences in DMT exposure, laboratory phenotype and acute-care utilisation. The primary analysis was restricted to adults with HbSS or HbSβ⁰-thalassaemia (HbSβ⁰-thal).

Methods: The dataset comprised 4,007 adults aged ≥18 years, including 3,038 from the US GRNDaD registry and 969 from the UK SCD Natural History Study (Cooperative Understanding of SCD Internationally, CoUSIn). Patient-level variables were mapped to common definitions. Current hydroxyurea, chronic transfusion and crizanlizumab use, latest blood results and healthcare utilisation were compared. Acute-care utilisation comprised emergency department or day unit/infusion centre attendances. High admission burden was defined as ≥2 admissions in the latest recorded 12-month interval. Logistic regression compared high admission burden between cohorts, adjusting for age and sex.

Results: The analysis comprised 2,633 adults with HbSS or HbSβ⁰-thal; 1,996 from the US and 637 from the UK. UK participants were older, with median age 36 versus 32 years in the US (p<0.001). 56% of both cohorts were female. HbSβ⁰-thal accounted for 6.7% of the US cohort and 1.3% of the UK cohort (p<0.001).

DMT exposure was higher in the US. Hydroxyurea was used by 61% of US participants versus 49% in the UK, while chronic transfusion was used by 25% (US) versus 22% (UK). Seventy-eight per cent of US participants were receiving either hydroxyurea or chronic transfusion compared with 67% in the UK (all p<0.001). Crizanlizumab use was 6.2% in the US versus 0.3% in UK.

Acute-care utilisation was higher in the US. Among those with recorded data, mean visits per year were 4.8 (US) versus 0.8 (UK) with medians of 1 (IQR 0–5) versus 0 (0–1). Zero visits were recorded for 556/1,996 (27.9%) US participants versus 218/637 (34.2%) UK participants, while ≥10 visits were recorded for 235/1,996 (11.8%) US participants versus 3/637 (0.5%) UK participants. 

Hospital admissions were also higher in the US. Mean admissions were 1.9 (US) versus 0.7 (UK) with medians of 1 (IQR 0–2) versus 0 (0–1). Zero admissions were recorded for 735/1,996 (36.8%) US participants versus 440/637 (69.1%) UK participants, while ≥10 admissions were recorded for 67/1,996 (3.4%) US participants versus 5/637 (0.8%) UK participants. High admission burden was recorded for 533/1,996 (26.7%) US participants versus 106/637 (16.6%) UK participants. After adjustment, US cohort membership was associated with higher odds of high admission burden (OR 2.47, 95% CI 1.96–3.14; p<0.001). Younger age was also associated with high burden, whereas sex was not.

Laboratory markers were similar in the two cohorts. In the US versus UK, median haemoglobin was 90 versus 91 g/L (p=0.003), reticulocyte count 223 versus 230 ×10⁹/L (p=0.4), bilirubin 39 versus 38 µmol/L (p=0.2), LDH 370 versus 380 U/L (p=0.030), creatinine 59 versus 61 µmol/L (p=0.072) and HbF 6.1 versus 5.3% (p=0.002). Median white cell count was higher in the US than the UK (9 versus 8 ×10⁹/L), as were neutrophil count (5 versus 4 ×10⁹/L) and platelet count (345 versus 299 ×10⁹/L; all p<0.001), while ALT (20 versus 24 IU/L, p<0.001) and urine albumin:creatinine ratio (3 versus 4 mg/mmol, p=0.002) were lower in the US.

Conclusions: In this international study of adults with HbSS or HbSβ⁰-thal, the US cohort had higher DMT exposure and acute-care utilisation than the UK cohort. Differences in admission burden persisted after adjustment for age and sex. Laboratory markers were similar. These findings describe variation between healthcare settings. Results should not be interpreted as evidence of comparative DMT effectiveness as treatment indications, timing, duration and adherence were not evaluated. Differences in data completeness, care pathways, access, healthcare-system organisation and social determinants of health warrant consideration in further longitudinal analyses.

Acknowledgments: The authors thank the participants, investigators and study teams of the US SCD GRNDaD Registry and UK SCD Natural History Study.

Alvin M Katumba, MBBS MRCP MRes: No relevant conflicts of interest to declare.